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University of British Colhis study sought to assess the independent effect of high-density lipoprotein-cholesterol (HDL-C) level on
cardiovascular risk in patients with stable ischemic heart disease (SIHD) who were receiving optimal medical
therapy (OMT).Background Although lowHDL-C level is a powerful and independent predictor of cardiovascular risk, recent data suggest that thismay
not apply when low-density lipoprotein-cholesterol (LDL-C) is reduced to optimal levels using intensive statin therapy.Methods We performed a post-hoc analysis in 2,193 men and women with SIHD from the COURAGE trial. The primary outcome
measurewas the composite of death from any cause or nonfatalmyocardial infarction (MI). The independent association
betweenHDL-C levelsmeasured after 6months on OMT and the rate of cardiovascular events after 4 yearswas assessed.
Similar analyses were performed separately in subjects with LDL-C levels below 70 mg/dl (1.8 mmol/l).Results In the overall population, the rate of death/MI was 33% lower in the highest HDL-C quartile as compared with the
lowest quartile, with quartile of HDL-C being a signiﬁcant, independent predictor of death/MI (p ¼ 0.05), but with no
interaction for LDL-C category (p ¼ 0.40). Among subjects with LDL-C levels <70 mg/dl, those in the highest quintile
of HDL-C had a 65% relative risk reduction in death or MI as compared with the lowest quintile, with HDL-C quintile
demonstrating a signiﬁcant, inverse predictive effect (p ¼ 0.02).Conclusions In this post-hoc analysis, patients with SIHD continued to experience incremental cardiovascular risk associated with
low HDL-C levels despite OMT during long-term follow-up. This relationship persisted and appeared more prominent
even when LDL-C was reduced to optimal levels with intensive dyslipidemic therapy. (Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation; NCT00007657) (J Am Coll Cardiol 2013;62:1826–33)
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1827Population-based studies consistently support high-density
lipoprotein cholesterol (HDL-C) as a signiﬁcant, strong, and
independent inverse predictor of cardiovascular risk, noting
that for every 1-mg/dl decrease in HDL-C level, risk of future
cardiovascular events increases by 2% to 3% (1–5). However,
the clinical interaction between low-density lipoprotein
cholesterol (LDL-C) andHDL-C level remains unclear, with
some analyses supporting a continuing predictive role of
HDL-C regardless of achieved LDL-C level, whereas others
suggesting that the effect of HDL-C may not be relevant
when LDL-C is reduced to very low levels, particularly when
potent statin therapy is used (6–10). This is especially impor-
tant because HDL-C levels are not substantially altered by
statin therapy and it can be hypothesized that persistently
low levels of HDL-C at baseline could be potentially respon-
sible for some of the residual risk observed in clinical trials
among statin-treated patients.See page 1842
SIHD = stable ischemic
heart diseaseThe COURAGE (Clinical Outcomes Utilizing Revas-
cularization and Aggressive Drug Evaluation) trial examined
the impact of optimal medical therapy (OMT) with or
without percutaneous coronary intervention (PCI) as the
initial management strategy in 2,287 patients with stable
ischemic heart disease (SIHD) (11). The main trial results
revealed no difference in the primary outcome of death
or myocardial infarction (MI) during a mean 4.6 years of
follow-up. Secondary prevention with OMT was applied
equally and intensively to both treatment groups, with excel-
lent adherence and no signiﬁcant differences in proportion of
patients achieving therapeutic goals (12). This post-hoc
analysis was conducted to assess the relationship between
the rate of adverse cardiovascular events and HDL-C levels
in SIHD patients receiving aggressive secondary prevention
with lifestyle and pharmacologic interventions, including
goal-directed statin therapy. The subset of patients who
achieved the optional LDL-C goal of <70 mg/dl established
by the Adult Treatment Panel (ATP) III were further
investigated to deﬁne the effect of HDL-C in presence
of optimally achieved and maintained levels of LDL-C on
statins, with or without ezetimibe (13).
Methods
The methods of the COURAGE trial (NCT00007657)
have been described previously (11–14). The study was
sponsored by the Department of Veterans Affairs Cooperativehonoraria from Merck, Amgen, Roche, Miraculins, Pﬁzer, sanoﬁ-aventis, Servier,
GlaxoSmithKline, and Valeant. Dr. Spertus owns the copyright to the Seattle
Angina Questionnaire; is a consultant for United Healthcare, St. Jude Medical,
Abbott Vascular, and Genentech; has received research grant support from Gilead,
Genentech, Amgen, and Eli Lilly & Company; has received support from the
American Heart Association, American College of Cardiology Foundation, United
Healthcare, Health Outcomes Science; and owns the copyright to Seattle AnginaStudies Program, with additional
funding from the Canadian
Institutes of Health Research and
supplemental support from several
pharmaceutical companies. An
independent data and safety
monitoring board monitored the
trial. Data management and
analyses were performed solely by
the data coordinating center and
were overseen by the trial’s exec-
utive committee, which had full
access to the data on completion
of the trial and vouched for their
accuracy. All patients had signiﬁ-
cant coronary artery disease with
evidence of myocardial ischemia.
Detailed inclusion and exclusion
criteria have been previously pub-
lished (11–14). The primary
outcomemeasure was the composite of death from any cause or
nonfatalMI.Subjectswere followed-up for amedianof 4.6 years
(range: 2.5 to 7.0 years) after randomization.
Details of risk factor modiﬁcation applied to both treat-
ment arms have been previously described (12). Lifestyle
counseling for diet, smoking cessation, glycemic control, and
weight loss was provided. All patients received anti-platelet
therapy (low-dose aspirin), anti-ischemic therapy (long-
acting metoprolol, amlodipine, and isosorbide mononitrate,
alone or in combination) and lisinopril or losartan for hyper-
tension, reduced ejection fraction, or secondary prevention.
Patients undergoing PCI also received clopidogrel, in accor-
dance with accepted treatment guidelines. The LDL-C target
in COURAGE was 60–85 mg/dl, which during the time the
trial was designed in the late 1990s, was more aggressive than
the ATP II recommendation of <100 mg/dl (15). In addi-
tion, by trial design, there were pre-deﬁned secondary
lipid targets for HDL-C (>40 mg/dl) and triglycerides
(<150 mg/dl). Ezetimibe, extended-release niacin, and
ﬁbrates were used in addition to statins, as needed clinically.
Thus, aggressive dyslipidemic therapy was instituted to lower
LDL-C as the principal treatment target, and to also target
both HDL-C raising and triglyceride lowering with addi-
tional agents to achieve secondary lipid targets.
Statistical analysis. For this post-hoc analysis, 2,193
subjects from among the total study population of
2,287 patients who had available HDL-C data were strati-
ﬁed into quartiles based on HDL-C levels on OMT
measured at 6 months post-randomization. In order toQuestionnaire; Kansas City Cardiomyopathy Questionnaire; and Position Analysis
Questionnaire. Dr. Chaitman is a consultant to Pﬁzer, Forest, Merck, Roche,
Sanoﬁ, and Takeda; and is a member of the speakers’ bureau for Gilead. All other
authors have reported that they have no relationships relevant to the contents of this
paper to disclose.
Manuscript received March 25, 2013; revised manuscript received July 8, 2013,
accepted July 23, 2013.
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1828standardize lipid levels during a time period after enrollment
when patients were being switched from other statins prior
to randomization to simvastatin, clinical characteristics and
lipid levels at month 6 were considered for baseline
comparison and endpoint events were left-censored at this
time point. Therefore, the average duration of follow-up for
this analysis was approximately 4 years, as compared with
the overall trial mean follow-up of 4.6 years. Cox regression
models were used to determine hazard ratios for endpoints
in each HDL-C quartile, adjusting for age, sex, BMI,
presence of hypertension, diabetes, current smoking,
and triglycerides at 6 months. LDL-C was not included
among the variables in the regression model. Instead, the
interaction between HDL-C and LDL-C levels on OMT
was explored using a stratiﬁed regression analysis withTable 1 Baseline Characteristics of Patients According to Quartiles
Quartile 1
<34.8 mg/dl
Quartile 2
34.9 to <40.7 mg/dl
Characteristic (N ¼ 551) (N ¼ 545)
Assigned to PCI þ OMT, n 265 280
Assigned to OMT, n 286 265
Male, % 94.6 91.2
White, % 89.8 84.0
Current smoker 35.6 26.7
Body mass index, kg/m2 30.8  5.2 30.2  5.0
Age, yrs 60.9  10.1 61.4  10.0
Cardiovascular history, %
Myocardial infarction 42.0 37.9
Prior CABG 14.2 9.4
Prior PCI 21.0 13.0
Stroke 6.0 5.9
Peripheral vascular disease 9.3 7.4
Hypertension 74.2 69.1
Heart failure 4.2 5.5
Diabetes 41.4 33.4
Angina 89.1 89.2
Drugs at study entry, %
Statin 67.0 68.6
Other anti-lipid drugs 9.6 7.6
Calcium blocker 31.9 32.7
ACEI or ARB 45.7 45.3
Beta blocker 73.0 72.9
Nitrates 60.1 60.5
Aspirin 87.3 88.6
Lipid values at 6 months, mg/dl
LDL-C 81.2  27.6 85.0  26.2
HDL-C 30.6  3.3 37.7  1.7
Total-C 148.3  34.5 154.0  32.2
Triglycerides 197.2  128.2 160.6  86.8
LDL-C to HDL-C 2.7  1.0 2.3  0.7
Total-C to HDL-C 4.9  .13 4.1  0.9
Anti-lipid drugs at 6 months, %
Statin 92.6 94.4
Other lipid lowering 35.4 27.4
Values are n, %, or mean  SD.
ACEI ¼ angiotensin-converting-enzyme inhibitor; ARB¼ angiotensin receptor blockers; CABG ¼ coronary
cholesterol; OMT ¼ optimal medical therapy; PCI ¼ percutaneous coronary intervention.pre-determined LDL-C categories (<70, 70 to 100, and
>100 mg/dl). Patients in the lowest category of LDL-C
(<70 mg/dl) were further analyzed by dividing them into
quintiles of HDL-C level (at 6 months) using identical
regression models. The independent associations between
death or MI and quartiles of the ratio of LDL-C to HDL-C
were also evaluated. Additionally, using numeric values of
HDL-C at 6 months, similarly adjusted Cox regression models
were executed to examine the relationship between continuous
HDL-C levels (at 6 months) and risk of death or MI.Results
Baseline characteristics. Baseline characteristics and lipid
levels of the subjects within quartiles of HDL-C are shownof HDL at 6 Months
Quartile 3
40.7 to <48.0 mg/dl
Quartile 4
48.0 to 94.0 mg/dl
Overall
12.0 to 94.0 mg/dl
(N ¼ 538) (N ¼ 558) (N ¼ 2192)
273 282 50.2 (%)
265 276 47.8 (%)
86.8 69.4 85.4
84.6 87.7 86.6
27.8 22.6 28.1
29.2  4.6 28.1  4.8 29.6  5.0
61.8  9.7 64.1  9.4 62.0  9.9
37.7 37.8 38.9
10.4 10.2 11.0
13.8 14.2 15.5
4.1 3.6 4.9
6.8 7.2 7.7
62.3 63.2 67.3
3.7 4.0 4.4
32.1 28.0 33.7
87.3 85.7 87.8
67.1 67.4 67.5
4.1 5.1 6.6
29.2 28.8 30.7
48.1 49.6 47.1
69.9 68.5 71.1
57.1 53.8 57.9
89.0 85.7 87.6
88.5  25.8 88.9  28.7 85.9  27.3
43.8  2.0 57.4  9.1 42.4  11.1
160.3  32.6 170.7  32.8 158.4  34.1
148.6  101.5 125.9  67.6 158.0  101.7
2.0  0.6 1.6  0.6 2.1  0.8
3.7  0.8 3.0  0.7 3.9  1.2
95.5 94.2 94.2
20.1 16.2 24.7
artery bypass grafting; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C¼ low-density lipoprotein
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1829in Table 1. Subjects in the lower HDL-C quartiles were
younger and more likely to be male with a greater proportion
of current smokers than those in higher HDL-C quartiles.
Those with low levels of HDL-C had higher baseline BMI,
higher triglycerides, and a greater prevalence of hypertension
and diabetes, features consistent with the metabolic
syndrome. Statin use was similar across HDL-C quartiles
at study entry and at 6 months, although overall usage
increased universally at the 6-month landmark. As expected,
the use of other drugs to treat serum lipids (including niacin
and ﬁbrates) was more than double in the lowest HDL-C
quartile as compared with the highest HDL-C quartile.
HDL-C quartile and risk of adverse clinical outcomes.
At the end of 4 years, the rate of the composite primary
endpoint was calculated for each HDL-C quartile in the
overall COURAGE population. In univariate analyses,
the primary endpoint of death or MI was 36% lower in the
highest HDL-C quartile compared with the lowest
(p ¼ 0.006). The secondary endpoints of death, MI or
stroke and death, MI, or ACS were lower by 33%
(p ¼ 0.01) and 34% (p ¼ 0.002), respectively, in the highest
versus lowest HDL-C quartiles. After multivariate adjust-
ment, those in the highest HDL-C quartile continued to
experience a signiﬁcant 33% reduction in the risk of the
primary endpoint (HR: 0.67; 95% conﬁdence interval [CI]:
0.47 to 0.95; p ¼ 0.02), as well as reductions in both
secondary endpoints (HR: 0.72; 95% CI: 0.52 to 1.01; p ¼
0.06 and HR: 0.72; 95% CI: 0.54 to 0.97; p ¼ 0.03,
respectively). Across all quartiles of HDL-C, the risk of
death or MI was signiﬁcantly lower among patients in
higher quartiles of HDL-C as compared with those in the
lower quartiles (p ¼ 0.02). After adjustment for other
variables, the quartile of HDL-C continued to retainFigure 1
Multivariate Analysis of the Relationship Between
Death or MI and Quartiles of HDL Cholesterol
Hazard ratios are adjusted for age, sex, body mass index, hypertension, diabetes,
current smoking, and triglycerides, and use lowest quartile (Q1) as referent. CI ¼
conﬁdence interval; HDL ¼ high-density lipoprotein; MI ¼ myocardial infarction.nominal statistical signiﬁcance as a predictor of death or MI
(p ¼ 0.05) (Fig. 1).
Effect of LDL-C. A regression analysis was conducted
using pre-speciﬁed LDL-C categories (<70 mg/dl,
n ¼ 634; 70 to 100 mg/dl, n ¼ 979; and >100 mg/dl,
n ¼ 573) to determine the interaction between LDL-C and
HDL-C. As expected, within each HDL-C quartile, those
in the lower LDL-C categories had a lower incidence
of death or MI compared with individuals within higher
LDL-C categories. Conversely, among patients in the same
LDL-C category, those belonging to higher HDL-C
quartiles experienced a greater protective effect from death
or MI compared with their counterparts in lower HDL-C
quartiles (Fig. 2). Overall, the effect of HDL-C quartile
on death or MI was independent, with no apparent inter-
action with LDL-C category (p ¼ 0.40). Further, when
using actual values of HDL-C and LDL-C in a continuous
regression model, LDL-C level at 6 months did not have
any signiﬁcant effect on the inverse predictive effect of
HDL-C (p ¼ 0.37).
In the subgroup of patients who achieved the optimal
LDL-C goal of <70 mg/dl, quintiles were created based on
HDL-C level at 6 months. In univariate analyses, patients in
the highest quintile of HDL-C had a 67% relative risk
reduction in the rate of death or MI versus those in the
lowest quintile (HR: 0.33; 95% CI: 0.16 to 0.66; p ¼ 0.002),
along with a 66% relative risk reduction in the composite
of death, MI, or stroke (HR: 0.34; 95% CI: 0.17 to 0.67;
p ¼ 0.002) and a 45% relative risk reduction in the com-
posite of death, MI, or ACS (HR: 0.55; 95% CI: 0.31 to
0.99; p ¼ 0.05). Even after adjustment for covariates, those
in the highest quintile of HDL-C had a 65% reduction
in the rate of the primary endpoint (HR: 0.35; 95% CI:Figure 2
Relationship Between HDL-C Quartiles and Death or
MI Across Categories of LDL-C
The effect of HDL-C quartile on death or MI was independent, with no apparent
interaction with LDL-C category (p ¼ 0.40). LDL ¼ Low-density lipoprotein; other
abbreviations as in Figure 1.
Figure 3
Multivariate Analysis of the Relationship Between
Death or MI and Quintiles of HDL-C Among Patients
With LDLCholesterol <70 mg/dl
Hazard ratios are adjusted for age, sex, body mass index, hypertension, diabetes,
current smoking, and triglycerides, and use lowest quintile (Q1) as referent.
Abbreviations as in Figures 1 and 2.
Acharjee et al. JACC Vol. 62, No. 20, 2013
Low HDL-C in the COURAGE Trial November 12, 2013:1826–33
18300.17 to 0.74; p ¼ 0.006) and a 63% decrease in death, MI,
or stroke (HR: 0.37; 95% CI: 0.26 to 0.75; p ¼ 0.006). A
trend (43% relative risk reduction) towards lower death, MI,
or ACS was noted in the top HDL-C quintile compared
with the bottom HDL-C quintile (43%, HR: 0.57; 95% CI:
0.30 to 1.08; p ¼ 0.08). Across all HDL-C quintiles in the
lowest stratum of LDL-C, the risk of death or MI differed
signiﬁcantly in both unadjusted analyses (p ¼ 0.004), and
after adjustment for confounding factors (p ¼ 0.02) (Fig. 3).
For the primary endpoint of death or MI, the ratio of
LDL-C to HDL-C was examined for predictive effect. At
6 months post-randomization, the quartile ratio of LDL-CFigure 4 Kaplan-Meier Curves for Overall Trial Population
Expected freedom from death or myocardial infarction across quartiles of LDL-C/
HDL-C ratio (Q1–Q4) at 6 months. Hazard ratios are adjusted for age, sex, body
mass index, hypertension, diabetes, current smoking, and triglycerides, and use
the lowest quartile (Q1) as referent. Abbreviations as in Figures 1 and 2.to HDL-C was inversely related to expected freedom from
death or MI. After multifactorial adjustment, although the
boundaries for HRs related to individual quartiles could not
exclude unity, a signiﬁcant difference in survival persisted
across all quartiles of LDL-C/HDL-C ratio (p ¼ 0.04)
(Fig. 4).
Continuous HDL-C levels. Using 6-month HDL-C level
as a continuous variable, the risk of death or MI was
calculated for each 10 mg/dl increase in HDL-C. After
adjustment for covariates, a rise of 10 mg/dl in HDL-C was
associated with a potential risk reduction of 9.9% (95% CI:
9.8 to 10.0), with a strong trend toward statistical signiﬁ-
cance (p ¼ 0.08) in death or MI. In particular, among
subjects in the lowest LDL-C category of <70 mg/dl, a 10
mg/dl increment in HDL-C was associated with a statis-
tically signiﬁcant 9.8% (95% CI: 9.5 to 10.0; p ¼ 0.03)
reduction in risk of the primary endpoint in adjusted
analysis. Age, sex, BMI, diabetes, hypertension, current
smoking, LDL-C and triglycerides at 6 months post-
randomization did not have any signiﬁcant interaction
with the observed predictive effect of HDL-C.
Discussion
This post-hoc analysis from the COURAGE trial demon-
strates that a signiﬁcant inverse association exists between
plasma HDL-C levels and cardiovascular risk that is inde-
pendent of other confounders, including age, sex, BMI,
presence of hypertension, diabetes, current smoking, and
triglycerides in patients with SIHD who undergo long-term
follow-up. The predictive relationship of low levels of
HDL-C remained valid across varying LDL-C levels in the
present analysis, and appeared greater in magnitude in
patients where the primary guideline-recommended optimal
target of lipid-lowering therapy for patients with SIHD had
been achieved (LDL-C <70 mg/dl). The results also
remained consistent, regardless of whether 6-month HDL-C
levels were used as continuous variables or divided into
quartiles or quintiles.
Considerable residual risk persists among statin-treated
patients, with rates of cardiovascular events being approxi-
mately two-thirds to three-quarters that of placebo-treated
patients in clinical trials (16–24). Even with maximal sta-
tin therapy, over 22% of patients with recent ACS andw9%
patients with SIHD experience endpoint events after 2 years
and 5 years of follow-up, respectively, indicating that
reducing LDL-C alone may not prevent all prognostically
important vascular events (25,26). In addition, patients with
metabolic syndrome and diabetes, conditions generally
associated with low levels of HDL-C, have approximately
twice the level of excess risk compared with those without
these comorbidities (27).
Unlike the consistent inverse epidemiologic association
between HDL-C and cardiovascular risk in patients with
normal or elevated LDL-C levels, conﬂicting results have
been noted in the setting of low LDL-C levels. Among
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1831high-risk patients with recent ACS treated with high-dose
statins, 1 trial found no incremental predictive value of
HDL-C (7), whereas the other showed that HDL-C, but
not LDL-C, measured in the initial stage of ACS predicted
the risk of short-term recurrent cardiovascular events (28).
In intermediate-risk patients with SIHD, low HDL-C
levels were independently predictive of higher cardiovas-
cular risk, even when LDL-C levels were reduced to
<70 mg/dl (8). The difference in risk between the highest
and the lowest HDL-C quintile was diminished and failed
to reach statistical signiﬁcance among those on maximal
dose atorvastatin. Finally, in a lower-risk primary prevention
population, HDL-C levels were inversely related to vascular
risk only in patients receiving placebo, but not in patients
assigned to receive potent statin therapy with resultant very
low on-treatment LDL-C levels (6). A meta-analysis of 20
large trials conﬁrmed the signiﬁcant and independent
inverse association between low HDL-C levels and cardio-
vascular risk among statin-treated patients, with no evidence
of any modiﬁcation or attenuation by statin therapy (10).
The present ﬁndings complement the results of this meta-
analysis, extending the concept of incremental cardiovas-
cular risk associated with low levels of HDL-C in SIHD
patients treated with OMT, particularly among subjects in
the lowest quintile of HDL-C. Instead of just focusing on
ﬁxed-dose high-potency statin treatment, the COURAGE
trial used goal-directed LDL-C lowering within the
framework of comprehensive and aggressive risk factor
modiﬁcation, an ideal approach closer to what published
clinical practice guidelines support therapeutically. Regard-
less, those with lower levels of HDL-C continued to expe-
rience greater cardiovascular events, even when LDL-C was
reduced to <70 mg/dl.
Clinical trial evidence to support the beneﬁts of HDL-C
raising has been limited. The VA-HDL Intervention Trial
studied 2,531 male veterans with established coronary heart
disease, LDL-C 140 mg/dl, and HDL-C 40 mg/dl,
treated with gemﬁbrozil or placebo in the pre-statin era (29).
At 5 years, despite no change in LDL-C levels as compared
with baseline, a modest 6% relative increase in HDL-C and
a 31% relative decrease in triglycerides was associated with
a signiﬁcant 22% reduction in the primary endpoint of
cardiovascular mortality or MI. However, in the AIM-
HIGH (Atherothrombosis Intervention in Metabolic
Syndrome with Low HDL/High Triglycerides: Im-
pact on Global Health Outcomes) trial, in similar SIHD
patients pre-selected for low baseline levels of HDL-C,
there was no incremental clinical beneﬁt associated with
the co-administration of high-dose (1,500 to 2,000 mg/day)
extended-release niacin and simvastatin as compared with
simvastatin monotherapy during an abbreviated 3-year
follow-up for the trial primary endpoint of major cardio-
vascular events or any of the component secondary or tertiary
endpoints (30). More recently, the HPS-2 (Heart Protection
Study-2) investigators have presented study ﬁndings in more
than 25,000 subjects treated with simvastatin with or withoutniacin (and laropiprant) during a long-term 5-year follow-up,
and likewise failed to show incremental beneﬁt over statin
monotherapy (31). Importantly, in both AIM-HIGH and
HPS-2, patients had very low baseline LDL-C levels
(ranging from the low 60s to low 70s), and thus it remains
uncertain whether the potential clinical beneﬁts of HDL-C
raising therapies may be mitigated in this very low range of
LDL-C levels. It is also unclear if the results would have
been different in patients whose LDL-C values were not as
well-controlled or in those naïve to statin therapy. Choles-
teryl ester transfer protein (CETP) inhibitors anacetrapib
and evacetrapib, perhaps the most promising investigational
HDL-C raising therapies remain under study in large-scale
phase III clinical trials (32,33). However, the CETP inhib-
itor torcetrapib was shown previously to increase mortality
and, more recently, dalcetrapib was found to have no
incremental beneﬁt when added to statin therapy in ACS,
despite signiﬁcant HDL-C raising (34,35). These disap-
pointing results to date suggest that CETP inhibition as
a therapeutic strategy may not confer clinical beneﬁt, despite
signiﬁcant HDL-C raising. Alternatively, the negative
results in these 4 clinical trials raise the very real possibility
that, although low levels of HDL-C may be an important
epidemiologic risk marker, the concentration or content of
HDL in plasma alone may not be a reliable therapeutic target
for pharmacologic intervention to reduce clinical events.
Indeed, there are data to support HDL particle size and
number as a potentially better measure of cardiovascular risk
(36), though no clinical trials to date have enrolled patients
based on particle size determinants alone, nor have they
targeted changes in particle size/number as a measure of
treatment efﬁcacy. Lastly, it is possible that investigators have
not targeted patients with the lowest levels of HDL-C
(e.g., <30 mg/dl), an important subgroup of patients who
may be at the highest risk for cardiovascular events and in
whom the potential exists to demonstrate clinical beneﬁt
with a non-statin intervention.
Study limitations. The COURAGE trial was not designed
speciﬁcally to study the residual cardiovascular risk associated
with low levels of HDL-C, resulting in some limitations
inherent in this post-hoc analysis. It is possible that using 6-
month levels of HDL-C and LDL-C rather than baseline
levels obtained prior to randomization might have resulted in
different outcomes. However, because there was no effect of
PCI versus OMT on clinical outcomes, and the potential
contribution of cardiac events occurring within the ﬁrst
6 months of follow-up to overall long-term trial outcomes was
likely minimal, it is doubtful that censoring events within the
initial 6 months would have altered our ﬁndings. Although we
attempted to adjust for known confounders, the presence of
unmeasured differences could account, in part, for the addi-
tional cardiovascular risk noted in patients on OMT, and
therefore, could potentially inﬂuence the predictive value of
HDL-C levels. The role of the metabolic syndrome was not
separately assessed, although adjustments weremade for BMI,
triglycerides, diabetes, and hypertension. Additionally, no
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fractions, particle size, or functionality, all of which may have
effects independent of total plasma HDL-C levels. Although
our ﬁndings should be considered hypothesis-generating and
exploratory in nature, they may have important therapeutic
implications, in that this is one of the largest prospective trials
of SIHD patients in whom long-term clinical outcomes have
been assessed as a function of both low levels of HDL-C and
LDL-C.
Conclusions
Our analysis suggests that patients with SIHD continue to
experience signiﬁcant, long-term cardiovascular risk associ-
ated with low HDL-C levels despite optimal medical
therapy with proven secondary prevention modalities,
including aggressive lifestyle modiﬁcation and intensive
goal-directed statin treatment. The adverse clinical effect of
low baseline levels of HDL-C we observed persisted despite
adjustment for other baseline risk predictors, and was
demonstrable across the full range of LDL-C levels. When
LDL-C was reduced to optimally low levels (<70 mg/dl)
using intensive lipid-lowering therapy, the risk for subse-
quent cardiovascular events among those with low baseline
levels of HDL-C remained statistically and clinically
signiﬁcant and, in fact, appeared to be magniﬁed. Thus,
further prospective study is needed to more precisely identify
those patients with either very low levels of HDL-C or
abnormal HDL particle composition who may be consid-
ered appropriate candidates for future therapeutic interven-
tions to improve clinical outcomes.
Reprint requests and correspondence: Dr. William E. Boden,
Department of Medicine, Samuel Stratton VA Medical Center,
113 Holland Avenue, Albany, New York 12208. E-mail: William.
boden@va.gov.
REFERENCES
1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR.
High density lipoprotein as a protective factor against coronary heart
disease. The Framingham Study. Am J Med 1977;62:707–14.
2. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM,
Kannel WB. Prevalence of coronary heart disease in the Framingham
Offspring Study: role of lipoprotein cholesterols. Am J Cardiol 1980;
46:649–54.
3. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S,
Kannel WB. Incidence of coronary heart disease and lipoprotein
cholesterol levels. The Framingham Study. JAMA 1986;256:2835–8.
4. Gordon DJ, Probstﬁeld JL, Garrison RJ, et al. High-density lipopro-
tein cholesterol and cardiovascular disease. Four prospective American
studies. Circulation 1989;79:8–15.
5. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density
lipoprotein cholesterol as a predictor of coronary heart disease risk.
The PROCAM experience and pathophysiological implications for
reverse cholesterol transport. Atherosclerosis 1996;124 Suppl:
S11–20.
6. Ridker PM, Genest J, Boekholdt SM, et al., for the JUPITER Trial
Study Group. HDL cholesterol and residual risk of ﬁrst cardiovascular
events after treatment with potent statin therapy: an analysis from the
JUPITER trial. Lancet 2010;376:333–9.7. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM,
Braunwald E, for the TIMI Study Group. Prognostic utility of apoB/
AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as
predictors of clinical risk in patients receiving statin therapy after acute
coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler
Thromb Vasc Biol 2009;29:424–30.
8. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low
levels of LDL cholesterol, and cardiovascular events. N Engl J Med
2007;357:1301–10.
9. deGoma EM, Leeper NJ, Heidenreich PA. Clinical signiﬁcance of
high-density lipoprotein cholesterol in patients with low low-density
lipoprotein cholesterol. J Am Coll Cardiol 2008;51:49–55.
10. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy
does not alter the association between low levels of high-density lipo-
protein cholesterol and increased cardiovascular risk. Ann Intern Med
2010;153:800–8.
11. Boden WE, O’Rourke RA, Teo KK, et al., for the COURAGE Trial
Research Group. Optimal Medical Therapy with or without PCI for
stable coronary disease. N Engl J Med 2007;356:1503–16.
12. Maron DJ, Boden WE, O’Rourke RA, et al., for the COURAGE
Trial Research Group. Intensive multifactorial intervention for stable
coronary artery disease: optimal medical therapy in the COURAGE
(Clinical Outcomes Utilizing Revascularization and Aggressive Drug
Evaluation) trial. J Am Coll Cardiol 2010;55:1348–58.
13. Grundy SM, Cleeman JI, Merz CN, et al., for the Coordinating
Committee of the National Cholesterol Education Program. Impli-
cations of recent clinical trials for the National Cholesterol Education
Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol
2004;44:720–32.
14. Boden WE, O’Rourke RA, Teo KK, et al. Design and rationale of the
Clinical Outcomes Utilizing Revascularization and Aggressive DruG
Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies
Program no. 424. Am Heart J 2006;151:1173–9.
15. National Cholesterol Education Program. Second Report of the Expert
Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;
89:1333–445.
16. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and
stroke events with atorvastatin in hypertensive patients who have
average or lower-than-average cholesterol concentrations, in the Anglo-
Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm
(ASCOT-LLA): a multicentre randomised controlled trial. Lancet
2003;361:1149–58.
17. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on
coronary events after myocardial infarction in patients with average
cholesterol levels. N Engl J Med 1996;335:1001–9.
18. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart
disease with pravastatin in men with hypercholesterolemia. N Engl J
Med 1995;333:1301–7.
19. Downs JR, Clearﬁeld M, Weis S, et al. Primary prevention of acute
coronary events with lovastatin in men and women with average choles-
terol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615–22.
20. Randomised trial of cholesterol lowering in 4444 patients with coro-
nary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet 1994;344:1383–9.
21. The Lipid Research Clinics Coronary Primary Prevention Trial results.
I. Reduction in incidence of coronary heart disease. JAMA 1984;251:
351–64.
22. Baigent C, Keech A, Kearney PM, et al. Efﬁcacy and safety of
cholesterol-lowering treatment: prospective meta-analysis of data from
90,056 participants in 14 randomised trials of statins. Lancet 2005;366:
1267–78.
23. Baigent C, Blackwell L, Emberson J, et al. Efﬁcacy and safety of more
intensive lowering of LDL cholesterol: a meta-analysis of data from
170,000 participants in 26 randomised trials. Lancet 2010;376:
1670–81.
24. Libby PJ. The forgotten majority: unﬁnished business in cardiovascular
risk reduction. J Am Coll Cardiol 2005;46:1225–8.
25. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering
with atorvastatin in patients with stable coronary disease. N Engl J Med
2005;352:1425–35.
26. Cannon CP, Braunwald E, McCabe CH, et al., for the Pravastatin or
Atorvastatin Evaluation and Infection Therapy-Thrombolysis in
Myocardial Infarction 22 Investigators. Intensive versus moderate lipid
JACC Vol. 62, No. 20, 2013 Acharjee et al.
November 12, 2013:1826–33 Low HDL-C in the COURAGE Trial
1833lowering with statins after acute coronary syndromes. N Engl J Med
2004;350:1495–504.
27. Deedwania P, Barter P, Carmena R, et al., for the Treating to New
Targets Investigators. Reduction of low-density lipoprotein cholesterol
in patients with coronary heart disease and metabolic syndrome:
analysis of the Treating to New Targets study. Lancet 2006;368:
919–28.
28. Olsson AG, Schwartz GG, Szarek M, et al. High-density lipoprotein,
but not low-density lipoprotein cholesterol levels inﬂuence short-term
prognosis after acute coronary syndrome: results from the MIRACL
Trial. Eur Heart J 2005;26:890–6.
29. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC,
Schaefer EJ, VA-HIT Study Group. Veterans Affairs High-Density
Lipoprotein Intervention Trial. Relation of gemﬁbrozil treatment and
lipid levels with major coronary events: VA-HIT: a randomized
controlled trial. JAMA 2001;285:1585–91.
30. AIM-HIGH Investigators, Boden WE, Probstﬁeld JL, et al. Niacin in
patients with low HDL cholesterol levels receiving intensive statin
therapy. N Engl J Med 2011;365:2255–67.
31. Armitage J, for the HPS2-THRIVE Collaborative Group. HPS2-
THRIVE: Randomized placebo-controlled trial of ER Niacin and
laropriprant in 25,673 patients with pre-existing cardiovascular disease.Abstract presented at: American College of Cardiology Scientiﬁc
Session 2013; March 9, 2013; San Francisco, CA.
32. Cannon CP, Dansky HM, Davidson M, et al., for the DEFINE
Investigators. Design of the DEFINE trial: determining the EFﬁcacy
and tolerability of CETP INhibition with AnacEtrapib. Am Heart J
2009;158:513–9.
33. Eli Lilly and Company. A Study of Evacetrapib in High-Risk Vascular
Disease (ACCELERATE). Available at: http://clinicaltrials.gov/show/
NCT01687998. Accessed March 24, 2013.
34. Barter PJ, Caulﬁeld M, Eriksson M, et al., for the ILLUMINATE
Investigators. Effects of torcetrapib in patients at high risk for coronary
events. N Engl J Med 2007;357:2109–22.
35. Schwartz GG, Olsson AG, Abt M, et al., for the dal-OUTCOMES
Investigators. Effects of dalcetrapib in patients with a recent acute
coronary syndrome. N Engl J Med 2012;367:2089–99.
36. deGoma EM, Rader DJ. High-density lipoprotein particle number:
a better measure to quantify high-density lipoprotein? J Am Coll
Cardiol 2012;60:517–20.Key Words: HDL cholesterol - residual risk - stable ischemic heart
disease.
